Poster
133
(#133) Economic Evaluation of Dyanavel XR for the Treatment of Attention-Deficit/Hyperactivity Disorder in US driver performance
Psych Congress 2025
Abstract: BACKGROUND: ADHD is linked to high-risk driving and motor vehicle accidents, totaling $340 billion in costs in 2019. DYANAVEL XR (DXR) showed a 43% lower crash risk compared to placebo in a randomized trial, with a crash rate comparable to non-ADHD drivers. Standard of care (SOC)-treated patients had a 52% higher crash risk than non-ADHD drivers. This analysis evaluated the economic benefits of DXR in reducing crash rates compared to SOC or no treatment.
METHODS: A cost-impact model estimated one-year crash-related outcomes for DXR-treated patients vs SOC-treated or untreated individuals. Crash risks were assumed to align with trial and literature data: DXR-treated patients matched non-ADHD risk, while untreated and SOC-treated patients had 99% and 52% higher risks, respectively. Outcomes included cost-impact, and the number of crashes, injuries, and fatalities avoided for each arm.
RESULTS: Treatment with DXR would avoid 0.82 crashes, 0.016 injuries, and 0.036 fatalities annually compared to untreated patients, and 0.036 crashes, 0.007 injuries, and 0.0001 fatalities per year compared to SOC-treated patients. When compared to an ADHD population of 25% SOC- and 75% untreated patients, DXR patients would save an average of $4581/person/year. When the value of quality-of-life improvement is considered, savings increase over 7-fold.
CONCLUSIONS: The findings emphasize the dual importance of addressing ADHD as a public safety concern and ensuring access to treatments that improve functional outcomes. The economic model shows that DXR is cost-saving compared to untreated patients and SOC-treated patients by reducing the number of motor vehicle crashes in the ADHD population.
Short Description: ADHD is associated with high-risk driving behavior and costly motor vehicle accidents. DYANAVEL XR (DXR) is a once-daily fast-acting amphetamine developed for ADHD treatment. A randomized controlled trial showed that DXR patients were 43% less likely to crash during a driving simulation compared to individuals taking placebo. This study evaluates the economic benefits attributable to improved driving abilities and avoided crashes in DXR patients compared to untreated patients or those treated with standard of care.
Name of Sponsoring Organization(s): This study was funded by Tris Pharma, Inc.
METHODS: A cost-impact model estimated one-year crash-related outcomes for DXR-treated patients vs SOC-treated or untreated individuals. Crash risks were assumed to align with trial and literature data: DXR-treated patients matched non-ADHD risk, while untreated and SOC-treated patients had 99% and 52% higher risks, respectively. Outcomes included cost-impact, and the number of crashes, injuries, and fatalities avoided for each arm.
RESULTS: Treatment with DXR would avoid 0.82 crashes, 0.016 injuries, and 0.036 fatalities annually compared to untreated patients, and 0.036 crashes, 0.007 injuries, and 0.0001 fatalities per year compared to SOC-treated patients. When compared to an ADHD population of 25% SOC- and 75% untreated patients, DXR patients would save an average of $4581/person/year. When the value of quality-of-life improvement is considered, savings increase over 7-fold.
CONCLUSIONS: The findings emphasize the dual importance of addressing ADHD as a public safety concern and ensuring access to treatments that improve functional outcomes. The economic model shows that DXR is cost-saving compared to untreated patients and SOC-treated patients by reducing the number of motor vehicle crashes in the ADHD population.
Short Description: ADHD is associated with high-risk driving behavior and costly motor vehicle accidents. DYANAVEL XR (DXR) is a once-daily fast-acting amphetamine developed for ADHD treatment. A randomized controlled trial showed that DXR patients were 43% less likely to crash during a driving simulation compared to individuals taking placebo. This study evaluates the economic benefits attributable to improved driving abilities and avoided crashes in DXR patients compared to untreated patients or those treated with standard of care.
Name of Sponsoring Organization(s): This study was funded by Tris Pharma, Inc.
